Stopping GLP-1 weight-loss drugs causes weight regain four times faster than ending exercise, with most individuals returning to their original weight within 18 months, highlighting the need for long-term management strategies.
Novo Nordisk, the pharmaceutical company that makes Levemir insulin, has announced it will discontinue the drug in the U.S. due to global manufacturing constraints and the availability of other forms of insulin, leaving thousands of diabetes patients like Stacey Silverman worried about finding a replacement. The discontinuation of Levemir highlights the challenges insulin-dependent patients face in accessing affordable insulin, despite recent price cuts by major insulin manufacturers. Families and advocates are concerned about losing a drug that has worked well for many patients, as drug companies often discontinue older versions of insulin when they develop newer, more expensive versions.